If you have been reading about alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-14. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
== External links == Amino acid metabolism Chapter on Amino acid catabolism in Biochemistry by Jeremy Berg, John Tymoczko, Lubert Stryer. Fourth ed. by Lubert Stryer. ISBN 0-7167-4955-6 Accessed 2007-03-17 Amino acid metabolism
In December 1990, Iraq made a proposal to withdraw from Kuwait provided foreign troops left the region and that an agreement was reached regarding the Palestinian problem and the dismantlement of Israel's and Iraq's weapons of mass destruction. The White House rejected the proposal. The PLO's Yasser Arafat expressed that neither he nor Saddam insisted that solving the Israel–Palestine issues should be a precondition to solving the issues in Kuwait, though he did acknowledge a "strong link" between these problems. The US and UK stuck to their position there would be no negotiations until Iraq withdrew, and should not grant Iraq concessions, lest they give the impression Iraq benefited from its military campaign. When US secretary of state James Baker met with Tariq Aziz in Geneva, for last minute peace talks in early 1991, Aziz reportedly made no concrete proposals and did not outline any hypothetical Iraqi moves. On 14 January 1991, France proposed that the UN Security Council call for "a rapid and massive withdrawal" from Kuwait along with a statement to Iraq that Council members would bring their "active contribution" to a settlement of the region's other problems, "in particular, of the Arab–Israeli conflict and in particular to the Palestinian problem by convening, at an appropriate moment, an international conference" to assure "the security, stability and development of this region of the world." The proposal was supported by Belgium, Germany, Spain, Italy, Algeria, Morocco, Tunisia, and several non-aligned states.
=== Imprinting === Molecular imprinting describes a process by which a host is constructed from small molecules using a suitable molecular species as a template. After construction, the template is removed leaving only the host. The template for host construction may be subtly different from the guest that the finished host binds to. In its simplest form, imprinting uses only steric interactions, but more complex systems also incorporate hydrogen bonding and other interactions to improve binding strength and specificity.
== Distribution and habitat == Psilocybe cubensis is a pan-tropical species, occurring in the Gulf Coast states and southeastern United States, Mexico, in the Central American countries of Belize, Costa Rica, Panamá, El Salvador and Guatemala, the Caribbean countries Cuba, the Dominican Republic, Puerto Rico, Guadalupe, Martinique, and Trinidad, in the South American countries of Argentina, Bolivia, Brazil, Colombia, French Guiana, Paraguay, Uruguay and Peru, Southeast Asia, including Thailand, Vietnam, Cambodia and Malaysia, India, Australia, Fiji, and possibly Nepal and Hawaii. Psilocybe cubensis is found on cow (and occasionally horse) dung, sugar cane mulch or rich pasture soil, with mushrooms appearing from February to December in the northern hemisphere, and November to April in the southern hemisphere. In Asia, the species grows on water buffalo dung. Along with other fungi that grow on cow dung, P. cubensis is thought to have colonized Australia with the introduction of cattle there, 1800 of which were on the Australian mainland by 1803—having been transported there from the Cape of Good Hope, Kolkata and the American west coast. In Australia, the species grows between northern Queensland to southern New South Wales. In March 2018, several Psilocybe cubensis specimens were collected in Zimbabwe in the Wedza District of Mashonaland East province, approx. 120 km southeast of Harare. This was the first reported occurrence of a psilocybin mushroom in Zimbabwe.
A long-chain fatty acid is dehydrogenated to create a trans double bond between C2 and C3. This is catalyzed by acyl CoA dehydrogenase to produce trans-delta 2-enoyl CoA. It uses FAD as an electron acceptor and it is reduced to FADH2. Trans-delta 2-enoyl CoA is hydrated at the double bond to produce L-3-hydroxyacyl CoA by enoyl-CoA hydratase. L-3-hydroxyacyl CoA is dehydrogenated again to create 3-ketoacyl CoA by 3-hydroxyacyl CoA dehydrogenase. This enzyme uses NAD as an electron acceptor. Thiolysis occurs between C2 and C3 (alpha and beta carbons) of 3-ketoacyl CoA. Thiolase enzyme catalyzes the reaction when a new molecule of coenzyme A breaks the bond by nucleophilic attack on C3. This releases the first two carbon units, as acetyl CoA, and a fatty acyl CoA minus two carbons. The process continues until all of the carbons in the fatty acid are turned into acetyl CoA. This acetyl-CoA then enters the mitochondrial tricarboxylic acid cycle (TCA cycle). Both the fatty acid beta-oxidation and the TCA cycle produce NADH and FADH2, which are used by the electron transport chain to generate ATP. Fatty acids are oxidized by most of the tissues in the body. However, some tissues such as the red blood cells of mammals (which do not contain mitochondria) and cells of the central nervous system do not use fatty acids for their energy requirements, but instead use carbohydrates (red blood cells and neurons) or ketone bodies (neurons only).
Sources: en.wikipedia.org
The simultaneous failures of SVB and New York's Signature Bank raised concern about the condition of other regional banks, with particular attention to First Republic Bank and Western Alliance. Faced with the possibility of a broader loss of confidence, on March 12 the Treasury granted the FDIC an exception allowing it to guarantee the uninsured deposits of both failed banks and to cover the expense through special assessments on other member banks. On March 13 the FDIC transferred SVB assets to a new bridge bank, Silicon Valley Bridge Bank, N.A., and appointed Tim Mayopoulos as CEO. The bridge bank consolidated insured and uninsured deposits into a single institution, making it more attractive to prospective buyers. There is a dispute about whether the U.S. government's guarantee to insure depositors in full, rather than just the $250,000 per account protected by law, qualifies as a bailout. President Joe Biden denied the term bailout applies in this particular case. Treasury Secretary Janet Yellen had already ruled out bailing out SVB. Silicon Valley Bank's overseas subsidiaries held $13.9 billion in deposits. The Bank of England issued a statement that it sought a court order to place the United Kingdom subsidiary of the bank into a Bank Insolvency Procedure. Shanghai Pudong Development Bank issued a statement that its joint operations with SVB, chaired by its own Shanghai-based chairman, were not affected by the collapse as of March 11. Canadian regulator Office of the Superintendent of Financial Institutions (OSFI) temporarily seized control of SVB Canada on March 12.
=== Reducing gastric reflux === The stomach produces gastric juice, a mixture consisting of gastric acid (mainly hydrochloric acid), lipase, and pepsin to enable food digestion. Constriction of the lower esophageal sphincter protects the esophageal mucosa by preventing reflux, the backflow of acid and gastric contents into the esophagus. The acute angle of His and the lower crura of the diaphragm also help this sphincteric action.
==== Bretisilocin ==== In March 2026, bretisilocin entered European Medicines Agency's priority medicines (PRIME) scheme for major depressive disorder, while a phase 2 clinical trial was still ongoing.
The Southwest United States is a significant source of turquoise; Arizona, California (San Bernardino, Imperial, Inyo counties), Colorado (Conejos, El Paso, Lake, Saguache counties), New Mexico (Eddy, Grant, Otero, Santa Fe counties) and Nevada (Clark, Elko, Esmeralda County, Eureka, Lander, Mineral County and Nye counties) are (or were) especially rich. The deposits of California and New Mexico were mined by pre-Columbian Native Americans using stone tools, some local and some from as far away as central Mexico. Cerrillos, New Mexico, is thought to be the location of the oldest mines; prior to the 1920s, the state was the country's largest producer; it is more or less exhausted today. Only one mine in California, located at Apache Canyon, operates at a commercial capacity today. The turquoise occurs as vein or seam fillings, and as compact nuggets; these are mostly small in size. While quite fine material is sometimes found, rivalling Iranian material in both colour and durability, most American turquoise is of a low grade (called "chalk turquoise"); high iron levels mean greens and yellows predominate, and a typically friable consistency in the turquoise's untreated state precludes use in jewelry. Arizona is currently the most important producer of turquoise by value. Several mines exist in the state, two of them famous for their unique colour and quality and considered the best in the industry: the Sleeping Beauty Mine in Globe ceased turquoise mining in August 2012.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.